Molecular mechanisms of basic fibroblast growth factor effect on healing of ulcerative colitis in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 430-437

  Paunovic, Brankica ^a   Deng, Xiaoming ^a   Khomenko, Tetyana ^a   Ahluwalia, Amrita ^a   Tolstanova, Ganna ^a   Tarnawski, Andrzej ^a,b   Szabo, Sandor ^a,b   Sandor, Zsuzsanna ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; KI 67 ANTIGEN; MATRIX PROTEIN; MYELOPEROXIDASE; PROTEIN P27; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; FIBROBLAST; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL CYCLE; CELL PROLIFERATION; COLITIS, ULCERATIVE; COLON; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLAST GROWTH FACTOR 2; IODOACETAMIDE; NEOVASCULARIZATION, PHYSIOLOGIC; PEROXIDASE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054788701     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183665     Document Type: Article

References (40)

1. Ardizzone S and Bianchi Porro G (2005) Biologic therapy for inflammatory bowel disease. Drugs 65:2253-2286. (Pubitemid 41571985)
2. Barrientos S, Stojadinovic O, Golinko MS, Brem H, and Tomic-Canic M (2008) Growth factors and cytokines in wound healing. Wound Repair Regen 16:585-601.
3. Beauchamp RD, Sheng HM, Shao JY, Thompson EA, and Ko TC (1996) Intestinal cell cycle regulations. Interactions of cyclin D1, Cdk4, and p21Cip1. Ann Surg 223:620-628.
4. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653-660.
5. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, et al. (2006) Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130:2060-2073. (Pubitemid 43816964)
6. Deng X, Szabo S, Khomenko T, Jadus MR, and Yoshida M (2004) Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats. J Pharmacol Exp Ther 311:982-988. (Pubitemid 39612702)
7. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, and Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715. (Pubitemid 14035254)
8. Gospodarowicz D, Bialecki H, and Greenburg G (1978) Purification of the fibroblast growth factor activity from bovine brain. J Biol Chem 253:3736-3743. (Pubitemid 8346572)
9. Herrinton LJ, Liu L, Lewis JD, Griffin PM, and Allison J (2008) Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol 103:1998-2006.
10. Houchen CW, George RJ, Sturmoski MA, and Cohn SM (1999) FGF-2 enhances intestinal stem cell survival and its expression is induced after radiation injury. Am J Physiol Gastrointest Liver Physiol 276:G249-G258. (Pubitemid 29063623)
11. Hoy A, Leininger-Muller B, Kutter D, Siest G, and Visvikis S (2002) Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 40:2-8. (Pubitemid 34196441)
12. Ioachim EE, Katsanos KH, Michael MC, Tsianos EV, and Agnantis NJ (2004) Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features. Int J Colorectal Dis 19: 325-333. (Pubitemid 38868298)
13. Johnston PG, O'Brien MJ, Dervan PA, and Carney DN (1989) Immunohistochemical analysis of cell kinetic parameters in colonic adenocarcinomas, adenomas, and normal mucosa. Hum Pathol 20:696-700. (Pubitemid 19185300)
14. Kojima T, Watanabe T, Hata K, and Nagawa H (2007) Basic fibroblast growth factor enema improves experimental colitis in rats. Hepatogastroenterology 54:1373-1377. (Pubitemid 47203429)
15. Koutroubakis IE, Tsiolakidou G, Karmiris K, and Kouroumalis EA (2006) Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 12:515-523.
16. Kusstatscher S, Sandor Zs, Satoh H, and Szabo S (1994) Inhibition of endogenous basic fibroblast growth factor (bFGF) delays duodenal ulcer healing in rats: implications for a physiologic role of bFGF. Gastroenterology 106:A113.
17. Kusstatscher S, Sandor Z, Szabo S, Seddon A, and Böhlen P (1995) Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats. J Pharmacol Exp Ther 275:456-461.
18. Letterio JJ and Roberts AB (1998) Regulation of immune responses by TGF-. Annu Rev Immunol 16:137-161.
19. Matsuura M, Okazaki K, Nishio A, Nakase H, Tamaki H, Uchida K, Nishi T, Asada M, Kawasaki K, Fukui T, et al. (2005) Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology 128:975-986. (Pubitemid 40523548)
20. Mazur G, Wróbel T, Dziegiel P, Jeleń M, Kuliczkowski K, and Zabel M (2004) Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol 42:241-243. (Pubitemid 39481032)
21. Mikami T, Yoshida T, Shiraishi H, Tokuyama W, Motoori T, and Okayasu I (2006) Bottom-up cell proliferation with cyclin A and p27Kip1 expression in ulcerative colitis-associated dysplasia. Pathol Int 56:10-16.
22. Naito Y, Takagi T, and Yoshikawa T (2007) Molecular fingerprints of neutrophildependent oxidative stress in inflammatory bowel disease. J Gastroenterol 42: 787-798. (Pubitemid 47617456)
23. Papadakis KA and Targan SR (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51:289-298. (Pubitemid 30216038)
24. Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, and Carlson M (2007) Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest 67:810-820. (Pubitemid 350158774)
25. Peyrin-Biroulet L (2010) Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol 56:233-243.
26. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
27. Rico T, Green J, and Kirsner RS (2009) Vascular endothelial growth factor delivery via gene therapy for diabetic wounds: first steps. J Invest Dermatol 129:2084.
28. Sandor Z, Deng XM, Khomenko T, Tarnawski AS, and Szabo S (2006) Altered angiogenic balance in ulcerative colitis: a key to impaired healing. Biochem Biophys Res Commun 350:147-150. (Pubitemid 44466584)
29. Satoh H, Shino A, Sato F, Asano S, Murakami I, Inatomi N, Nagaya H, Kato K, Szabo S, and Folkman J (1997) Role of endogenous basic fibroblast growth factor in the healing of gastric ulcers in rats. Jpn J Pharmacol 73:59-71. (Pubitemid 27078011)
30. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, et al. (2009) VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 136:585-595.e5.
31. Shih DQ and Targan SR (2009) Insights into IBD pathogenesis. Curr Gastroenterol Rep 11:473-480.
32. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, and Klagsbrun M (1984) Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223:1296-1299. (Pubitemid 14163183)
33. Stallmach A, Hagel S, and Bruns T (2010) Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 24:167-182.
34. Szabo S, Folkman J, Vattay P, Morales RE, Pinkus GS, and Kato K (1994) Accelerated healing of duodenal ulcers by oral administration of a mutein of basic fibroblast growth factor in rats. Gastroenterology 106:1106-1111. (Pubitemid 24109300)
35. Szabo S, Folkman J, Vincze A, Sandor Zs, and Gombos Z (1997) Modulation of vascular factors by VEGF/VPF (vascular endothelial cell growth factor/vascular permeability factor) is sufficient for chronic ulcer healing and acute gastroprotection. Gastroenterology 112:A303.
36. Szabo S, Sakoulas G, Kusstatscher S, and Sandor Zs (1993) Effects of endogenous and exogenous basic fibroblast growth factor in ulcer healing. Eur J Gastroenterol Hepatol 5:S53-S57. (Pubitemid 24053360)
37. Szabo S and Sandor Z (1996) Basic fibroblast growth factor and PDGF in GI diseases. Baillieres Clin Gastroenterol 10:97-112. (Pubitemid 26125749)
38. Tolstanova G, Khomenko T, Deng X, Chen L, Tarnawski A, Ahluwalia A, Szabo S, and Sandor Z (2009) Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 328:749-757.
39. Vidrich A (2003) Signaling through FGFR3 is necessary for expansion of the epithelial stem cell compartment during normal intestinal development. Gastroenterology 124:A22.
40. Wong NA and Harrison DJ (2001) Colorectal neoplasia in ulcerative colitis-recent advances. Histopathology 39:221-234. (Pubitemid 34279656)